AABB monitors evolving issues and related federal regulations and recommendations and tracks federal agency practices and procedures. AABB works closely with FDA, the Centers for Disease Control and Prevention and other national experts and organizations to identify emerging threats to the safety of blood and biotherapies. The work of AABB’s committees promote strategies to support a stronger, safer supply of these life-saving resources. Close interaction with our member experts and federal agencies affords AABB a unique position from which to represent and support our membership and transfusion recipients.
AABB is a leading voice in advancing policies that support patients’ access to blood transfusions and biotherapies, as well as donor and patient safety and care. AABB represents the transfusion medicine and biotherapies community before a variety of federal agencies including the Food and Drug Administration, Department of Health and Human Services, Centers for Medicare and Medicaid Services, National Institutes of Health and Centers for Disease Control and Prevention as well as Congress. In addition, the Association works with other professional societies, hospitals, health care organizations, and payers to advance private sector policies to improve transfusion medicine and biotherapies care.